Cerecor to Present at the Jefferies Virtual Healthcare Conference
May 29 2020 - 7:00AM
Cerecor Inc. (NASDAQ: CERC) today announced that Michael F. Cola,
President and Chief Executive Officer, will present at the
Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at
2:30 p.m. EDT.
A live webcast of the presentation can be accessed
under "News/Events" page in the Investors section of the Company's
website at www.cerecor.com.
About Cerecor
Cerecor is a biopharmaceutical company focused on
becoming a leader in development and commercialization of
treatments for rare pediatric and orphan diseases. The Company is
advancing an emerging clinical-stage pipeline of innovative
therapies. The Company’s pediatric rare disease pipeline is led by
CERC-801, CERC-802 and CERC-803 (“CERC-800 programs”), which are
therapies for inborn errors of metabolism, specifically disorders
known as Congenital Disorders of Glycosylation (”CDGs”). The FDA
granted Rare Pediatric Disease Designation and Orphan Drug
Designation (“ODD”) to all three CERC-800 programs, thus
potentially qualifying the Company to receive a Priority Review
Voucher (“PRV”) upon approval of a new drug application (“NDA”).
The Company is also developing CERC-002, CERC-006 and CERC-007.
CERC-007 is an anti-IL-18 monoclonal antibody being developed for
the treatment of autoimmune inflammatory diseases such as Adult
Onset Stills Disease (“AOSD”) and Multiple Myeloma (“MM”). CERC-006
is a dual mTOR inhibitor being developed for the treatment of
complex Lymphatic Malformations. CERC-002 is an anti-LIGHT
monoclonal antibody being developed for the treatment of COVID-19
ARDS and Pediatric-onset Crohn’s Disease.
For more information about Cerecor, please visit
www.cerecor.com.
Forward-Looking Statements
This press release may include forward-looking
statements made pursuant to the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are statements that
are not historical facts. Such forward-looking statements are
subject to significant risks and uncertainties that are subject to
change based on various factors (many of which are beyond Cerecor’s
control), which could cause actual results to differ from the
forward-looking statements. Such statements may include, without
limitation, statements with respect to Cerecor’s plans, objectives,
projections, expectations and intentions and other statements
identified by words such as “projects,” “may,” “might,” “will,”
“could,” “would,” “should,” “continue,” “seeks,” “aims,”
“predicts,” “believes,” “expects,” “anticipates,” “estimates,”
“intends,” “plans,” “potential,” or similar expressions (including
their use in the negative), or by discussions of future matters
such as: the development of product candidates or products; timing
and success of trial results and regulatory review; potential
attributes and benefits of product candidates; and other statements
that are not historical. These statements are based upon the
current beliefs and expectations of Cerecor’s management but are
subject to significant risks and uncertainties, including: drug
development costs, timing and other risks, including reliance on
investigators and enrollment of patients in clinical trials, which
might be slowed by the COVID-19 pandemic; regulatory risks;
Cerecor's cash position and the need for it to raise additional
capital; general economic and market risks and uncertainties,
including those caused by the COVID-19 pandemic; and those other
risks detailed in Cerecor’s filings with the Securities and
Exchange Commission. Actual results may differ from those set forth
in the forward-looking statements. Except as required by applicable
law, Cerecor expressly disclaims any obligations or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Cerecor’s
expectations with respect thereto or any change in events,
conditions or circumstances on which any statement is based.
For media and investor
inquiries
James Harrell, Investor RelationsChief Commercial
OfficerCerecor Inc.jharrell@cerecor.com623.439.2220 office
Cerecor (NASDAQ:CERC)
Historical Stock Chart
From May 2024 to Jun 2024
Cerecor (NASDAQ:CERC)
Historical Stock Chart
From Jun 2023 to Jun 2024